Which shock drug is safest? large ICU trial aims to find out
NCT ID NCT02118467
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests four different drugs (norepinephrine, epinephrine, phenylephrine, and vasopressin) in ICU patients with shock that doesn't improve with fluids. The goal is to see which drug causes fewer dangerous heart rhythm problems and improves survival. About 836 adults will take part, and the drugs are given through a central line.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
norepinephrine, epinephrine, phenylephrine, vasopressin
What this could lead to
If successful, this could identify which vasoactive drug is safest for ICU shock patients, potentially reducing dangerous heart rhythm issues and improving survival.
What could go wrong
This is a single-center trial, so results may not apply everywhere. The drugs are already in use, so no major breakthrough is expected—just better guidance for doctors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact